Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2005, Pages 81-86

  Moreau, M ^a   Daminet, S ^b   Martel Pelletier, J ^c   Fernandes, J ^c   Pelletier, Jean Pierre ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b GHENT UNIVERSITY   (Belgium)

^c NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2 INHIBITOR; LICOFELONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM; DUODENUM INJURY; DUODENUM MUCOSA; DUODENUM ULCER; ENDOSCOPY; ENZYME INHIBITION; NONHUMAN; OCCULT BLOOD; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH; STOMACH MUCOSA; STOMACH MUCOSA INJURY; STOMACH ULCER; UPPER GASTROINTESTINAL BLEEDING;

ACETIC ACIDS; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOGS; DOUBLE-BLIND METHOD; DUODENOSCOPY; DUODENUM; GASTROSCOPY; LACTONES; LIPOXYGENASE INHIBITORS; PYRROLES; STOMACH; SULFONES; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 14844353986     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2004.00640.x     Document Type: Article

References (15)

1. Bertolini, A., Ottani, A. & Sandrini, M. (2001) Dual acting anti-inflammatory drugs: a reappraisal. Pharmacological Research, 44, 437-450.
2. Celotti, F. & Durand, T. (2003) The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins and Other Lipid Mediators, 71, 147-162.
3. Depre, M., Van Ehrich, E., Hecken, A., De Lepeleire, I., Dallob, A., Wong, P., Porras, A., Gertz, B.J. & De Schepper, P.J. (2000) Pharmacokinetics. COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. European Journal of Clinical Pharmacology, 56, 167-174.
4. Fiorucci, S., Distrutti, E., de Lima, O.M., Romano, M., Mencarelli, A., Barbanti, M., Palazzini, E., Morelli, A. & Wallace, J.L. (2003) Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. The FASEB Journal, 17, 1171-1173.
5. Forsyth, S.F., Guilford, W.G. & Lawoko, C.R.O. (1996) Endoscopic evaluation of the gastroduodenal mucosa following non-steroidal anti-inflammatory drug administration in the dog. New Zealand Veterinary Journal, 44, 179-181.
6. Gilroy, D.W. & Colville-Nash, P.R. (2000) New insights into the role of COX-2 in inflammation. Journal of Molecular Medicine, 78, 121-129.
7. Halpin, R.A., Geer, L.A., Zhang, K.E., Marks, T.M., Dean, D.C., Jones, A.N., Melillo, D., Doss, G. & Vyas, K.P. (2000) The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metabolism and Disposition, 28, 1244-1254.
8. Hudson, N., Balsitis, M., Everitt, S. & Hawkey, C.J. (1993) Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut, 34, 742-747.
9. Jovanovic, D.V., Fernandes, J.C., Martel-Pelletier, J., Jolicoeur, F.C., Reboul, P., Laufer, S., Tries, S. & Pelletier, J.P. (2001) In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1β synthesis. Arthritis and Rheumatism, 44, 2320-2330.
10. Martel-Pelletier, J., Lajeunesse, D., Reboul, P. & Pelletier, J.P. (2003) Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Annals of the Rheumatic Diseases, 62, 501-509.
11. Rainsford, K.D. (1993) Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. Agents and Actions, 39, C24-C26.
12. Simon, L.S., Lanza, F.L., Lipsky, P.E., Hubbard, R.C., Talwalker, S., Schwartz, B.D., Isakson, P.C. & Geis, G.S. (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis and Rheumatism, 41, 1591-1602.
13. Skelly, M.M. & Hawkey, C.J. (2003) COX-LOX inhibition: current evidence for an emerging new therapy. International Journal of Clinical Practice, 57, 301-304.
14. Tries, S. & Laufer, S. (2001) The pharmacological profile of ML3000: a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Inflammopharmacology, 9, 101-112.
15. Wallace, J.L., Carter, L., McKnight, W., Tries, S. & Laufer, S. (1994) ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. European Journal of Pharmacology, 271, 525-531.